Watch These Eli Lilly Price Levels as Stock Slumps on Tepid Sales Outlook

1. Eli Lilly lowered 2024 revenue forecast, raising concerns for investors. 2. Shares fell sharply after a breakdown below key technical levels. 3. Key support at $720 and $625 identified; resistance at $860 and $965. 4. Weight-loss drug sales slower than expected, impacting financial outlook. 5. Stock down over 16% since October despite a 32% rise last year.